Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.

What Was Tested

Researchers studied Clomiphene in this randomized controlled trial publication.

In women suffering from polycystic ovary syndrome (PCOS), correction of hyperinsulinemia results enhances spontaneous ovulation or alternatively, the responsiveness to ovulation induction agents such as clomiphene citrate (CC).

The researchers investigated the effect of rosiglitazone maleate on ovulation induction in overweight and obese, CC-resistant women with PCOS.

Who Took Part

The age groups tagged for this paper are teenagers and adults, women only.

Overweight and obese women with clinical and laboratory manifestations of PCOS who desired pregnancy and were resistant to CC.

Twenty-five women were randomized into two treatment groups.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Clomiphene study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Clomiphene, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Clomiphene group a baseline to be compared against.

The duration of the study was 2 months.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Clomiphene, Deamino Arginine Vasopressin, Dehydroepiandrosterone Sulfate, Fasting, Glycated Hemoglobin and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Clomiphene.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Fertility and sterility), a journal based in United States.

More context: all human trials.